GSK to Acquire Biotech Firm 35Pharma in $950 Million Deal

GSK has announced its agreement to acquire 35Pharma, a biotechnology company developing an early-stage treatment for high blood pressure, in a deal valued at $950 million. Bloomberg posted on X, highlighting the strategic move by GSK to expand its portfolio in the cardiovascular sector. The acquisition is expected to bolster GSK's pipeline with innovative therapies, aligning with its focus on addressing unmet medical needs. This transaction underscores GSK's commitment to enhancing its research and development capabilities in the biotech space.